Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Comparison of COVID-19 outcomes between racial groups in the COViMS registry

Research Alert

Newswise — Background: Risk factors previously identified for worse outcomes with SARS-CoV-2 infections include older age, male sex and specific comorbid conditions. An increased risk for poorer COVID-19 outcomes in people with multiple sclerosis (MS) are similar to the general population, but less is known about outcomes in minority groups with MS.

Objectives: To evaluate differences in outcomes of SARS-CoV-2 infection in non-Hispanic White and Black persons with multiple sclerosis.

Methods: COViMS is a North American registry for health care providers to report persons with MS who are infected with SARS-CoV-2, the virus that causes COVID-19 (cases). Cases are reported after 7 days and when the outcome of infection is reasonably certain. MS and clinically isolated syndrome cases were categorized using the Center for Disease Control and Prevention races (non-Hispanic Whites, and Black). Comorbidities related to COVID-19 outcomes were collected. Clinical outcomes examined were mortality alone, mortality and/or admissions to the intensive care unit (ICU) and mortality, ICU admissions and/or hospitalization. Age-adjusted mortality rates as of August 3, 2020 and 95% confidence intervals (CI) were calculated. Multivariable logistic regression was used to assess adjusted differences between races using odds ratios (OR) and 95% CIs. Covariates included sex, age, smoking (current, past, never), MS clinical course (relapsing, progressive), disease duration, ambulation (fully ambulatory, walks with assistance, non-ambulatory), individual comorbidities (cardiovascular disease, cerebrovascular disease, chronic kidney disease, chronic lung disease, diabetes, hypertension, morbid obesity), and disease modifying therapy use (yes vs no).

Results: Of 734 patients reported, 421 (57.4%) Whites, and 194 (26.5%) Black patients were reported. Black cases were more likely to be younger (p=0.002), never smokers (p=0.002), have shorter MS duration (p<0.001), a relapsing MS course (p=0.03) and have comorbidities (p<0.001) compared to Whites. A higher proportion of Black patients had hypertension (40.2% vs 19.5%, p<0.001), and morbid obesity (17.0% vs 9.5%, p=0.007). Mortality rates increased with age and were not statistically different between Whites and Blacks (p=0.156). Black race was associated with increased odds of mortality and/or ICU admission (OR 3.8 [95%CI: 1.60, 8.96], p=0.002) and mortality, ICU admission and/or hospitalization (OR 2.0 [95%CI: 1.14, 3.54], p=0.016) after adjustment for covariates.

Conclusions: Within the COViMS registry, Black MS patients were younger and more likely to have comorbidities than White MS patients. Black MS patients had an increased risk for poorer outcomes compared to Whites even after adjusting for comorbidities at the time of COVID-19.

Presenter:Amber Salter, Washington University School of Medicine, Department of Biostatistics, Biostatistics, 660 S. Euclid Ave, 63110, St. Louis, US



Filters close

Showing results

110 of 6074
Newswise: Connect Chicago Initiative Expands Community COVID-19 Testing
Released: 27-Jul-2021 4:45 PM EDT
Connect Chicago Initiative Expands Community COVID-19 Testing
Rush University Medical Center

As COVID-19 cases rise in the U.S., Connect Chicago — new initiative between the Chicago Department of Public Health, Rush University Medical Center, and Esperanza Health Centers — is aiming to redouble testing efforts in Chicago communities that need it most.

Newswise: California State University to Implement COVID-19 Vaccination Requirement for Fall 2021 Term
Released: 27-Jul-2021 1:35 PM EDT
California State University to Implement COVID-19 Vaccination Requirement for Fall 2021 Term
California State University (CSU) Chancellor's Office

California State University to Implement COVID-19 Vaccination Requirement for Fall 2021 Term

Released: 27-Jul-2021 12:55 PM EDT
Behind the COVID-19 Diagnostic for Testing Hundreds of People at a Time
The Fannie and John Hertz Foundation

Hertz Fellow Cameron Myhrvold and colleagues are advancing research that started long before the pandemic.

Released: 27-Jul-2021 12:35 PM EDT
T cell response not critical for immune memory to SARS-CoV-2 or recovery from COVID-19
American Society for Microbiology (ASM)

New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections.

Released: 27-Jul-2021 11:45 AM EDT
mRNA Vaccinations vs COVID-19 Risk in Teens – Vaccinations are Safer
Case Western Reserve University

Case Western Reserve University researchers have demonstrated that the risk for myocarditis/pericarditis (heart inflammation) among male teens (12-17) diagnosed with COVID-19 is nearly 6 times higher than their combined risk following first and second doses of an mRNA COVID-19 vaccination. The risk for myocarditis/pericarditis among girls (ages 12-17) is 21 times greater from COVID-19 than from vaccines.

Released: 27-Jul-2021 9:45 AM EDT
Twitter Study Tracks Early Days of COVID-19 Pandemic in U.S.
Binghamton University, State University of New York

Researchers at Binghamton University, State University of New York studied Twitter communications to understand the societal impact of COVID-19 in the United States during the early days of the pandemic.

Released: 27-Jul-2021 9:45 AM EDT
A First Report of COVID-19 Orbital Involvement Is Reported in the Journal of Craniofacial Surgery
Wolters Kluwer Health: Lippincott

A severe skin infection in the orbital area (around the eye) may represent an unusual complication of COVID-19, according to a patient report published in The Journal of Craniofacial Surgery. The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: “Baiya Vaccine” from Chula — a Testament of Thai Mastery — Coming this September
Released: 27-Jul-2021 8:55 AM EDT
“Baiya Vaccine” from Chula — a Testament of Thai Mastery — Coming this September
Chulalongkorn University

Chula Pharmacy prepares to test “Baiya Vaccine” a Thai vaccine against COVID–19 by “Baiya Phytofarm“, a Chula startup. The vaccines have been produced at the first plant in Asia that manufactures plant–based vaccines for humans. Clinical trials with volunteers and the research for the second–generation vaccine to fight the virus variants are to commence in September 2021.


Showing results

110 of 6074

close
2.49509